Search
Mepolizumab
go.drugbank.com/drugs/DB06612ApprovedInvestigationalMepolizumab was first approved by the FDA on November 4, 2015, as an add-on therapy for severe asthma and marketed under the brand name Nucala by GlaxoSmithKline. … The pathogenesis of eosinophilia is complex, but IL-5 is recognized as a key cytokine involved in the differentiation, recruitment, activation, and prolonged survival of eosinophils in peripheral tissue
Categories: Interleukin-5 AntagonistProducts: NUCALA SOLUTION FOR INJECTION IN PRE-FILLED PEN 100MG/ML, NUCALA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/MLATPase GET3
go.drugbank.com/bio_entities/BE0000750TargetHumansATPase required for the post-translational delivery of tail-anchored (TA) proteins to the endoplasmic reticulum (PubMed:17382883). Recognizes and selectively binds the transmembrane domain of TA proteins in the cytosol. This complex then...
Synonyms: hARSA-I, hASNA-IMagnesium chloride
go.drugbank.com/drugs/DB09407ApprovedInvestigationalMagnesium chloride salts are highly soluble in water and the hydrated form of magnesium chloride can be extracted from brine or sea water.
Mixtures: Dextrose and Electrolyte No. 48, K+36.8Albendazole
go.drugbank.com/drugs/DB00518ApprovedInvestigationalVet approvedA benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38)
Synonyms: O-methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate, 5-(propylthio)-2-carbomethoxyaminobenzimidazoleInternational brands: Ben-ADonepezil
go.drugbank.com/drugs/DB00843ApprovedInvestigationalDonepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia. … [L7916,L7937] A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia.
Mixtures: DOMINGO 5/5/80 MG EFERVESAN TABLET, 30 ADET, DOMINGO 5/5/80 MG EFERVESAN TABLET, 90 ADETCategories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingIcosapent
go.drugbank.com/drugs/DB00159ApprovedInvestigationalNutraceuticalImportant polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. … -2 and prostaglandin-2 families.
Mixtures: UltimateCare ONE NF, Se-Tan DHACategories: Non COX-2 selective NSAIDS, Fatty Acids, Omega-3Gemcitabine
go.drugbank.com/drugs/DB00441ApprovedInvestigationalGemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. … [L32960] The structure, metabolism, and mechanism of action of gemcitabine are similar to [cytarabine], but gemcitabine has a wider spectrum of antitumour activity.
Synonyms: 2'-Deoxy-2',2'-difluorocytidine, 4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-oneCategories: P-glycoprotein substrates with a Narrow Therapeutic Index, P-glycoprotein substratesTafenoquine
go.drugbank.com/drugs/DB06608ApprovedInvestigationalTafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group. … [A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsSecukinumab
go.drugbank.com/drugs/DB09029ApprovedInvestigational[A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). … [L39600] By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders.
Products: COSENTYX SOLUTION FOR INJECTION IN PREFILLED SYRINGE 150MG/ML, Fraizeron 150mg/ml solution for injection in pre-filled penVibrio cholerae CVD 103-HgR strain live antigen
go.drugbank.com/drugs/DB14443ApprovedInvestigational[L12801] Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. … [A244494] Vaxchora was later approved by the European Commission in April 2020.[L39729] It is indicated for individuals aged two years and older.[L12801]